Phase 2 Breast Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with advanced breast cancer of a type called adenocarcinoma, and who have already received appropriate prior treatment for their stage and type of cancer.
• People whose cancer has spread to other parts of the body or has come back in the local area, and where scans or other objective evidence show the cancer has continued to grow or spread during or after their most recent cancer treatment.
• People who have a good general level of functioning (able to carry out daily activities with little or no restriction) and who are expected to live for at least 12 weeks.
• People who have at least one area of cancer that can be measured or tracked using scans such as CT, MRI, X-ray, or physical examination.
• People whose menopausal status meets specific criteria — pre-menopausal women must be on a specific hormone-suppressing therapy (called a GnRH agonist) for at least 4 weeks before starting the study treatment and throughout the study; post-menopausal women must meet one of several defined criteria relating to age, time without periods, surgical removal of ovaries, or hormone levels (confirm with trial site).
• People whose breast cancer has been confirmed through a tissue or cell sample (biopsy or similar test) as adenocarcinoma.
• People of childbearing potential who agree to use at least one highly effective form of contraception during the trial.
• People whose tumour has been confirmed to be oestrogen receptor (ER)-positive, regardless of another hormone marker called progesterone receptor status.

Who may not be able to join:

• People who have already received two or more different CDK4/6 inhibitor treatments (a type of targeted cancer drug) for advanced disease.
• People who have previously been treated with the study drugs camizestrant or atirmociclib for advanced disease.
• People who have previously been treated with other next-generation drugs in a class called SERDs, or other experimental hormone-based cancer therapies, for advanced disease.
• People who have previously been treated with other experimental CDK inhibitor drugs (a type of targeted cancer therapy).
• People who are unable to swallow tablets or capsules.
• People who still have side effects rated as moderate or severe (Grade 2 or higher) from previous cancer treatments, with the exception of hair loss.
• People who have life-threatening cancer spread affecting vital organs.
• People who have serious or poorly controlled other health conditions.
• People who have a known allergy, intolerance, or medical reason preventing the use of camizestrant or atirmociclib.

Important: Always verify eligibility with the trial site directly before applying.